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1.1 INTRODUCTION 
Clinical traits associated with androgens, acne and hirsutism, are important 
diagnostic features of polycystic ovary syndrome (PCOS). Current data suggests that the 
majority of patients with hirsutism, between 75-85%, and between 20-40% of patients 
with persistent acne only, have PCOs .<t) Androgens are one of the determining elements 
in the development of acne due to the influence of two major factors in acne 
pathogenesis: enhanced follicular keratosis and increased sebum production.(2) The 
growth of sexual hair is also primarily dependent on the presence of androgens. In 
androgen responsive areas, testosterone initiates growth, increases diameter and 
pigmentation of the keratin column and, in all probability, increases the rate of matrix 
cell mitoses in all but scalp hair.(2) As androgens are necessary for the development of 
cutaneous features found in polycystic ovary syndrome (PCOS), it would be expected 
that women with severe forms of clinical hyperandrogenism would have more elevated 
plasma levels of specific androgens.(2) Several studies have reported a correlation 
between hirsuitism and/or acne and circulating androgen levels with inconsistent 
results.<6·8) The variances in published results indicate hyperandrogenism not only 
reflects circulating androgen levels, but is also influenced by the peripheral metabolism 
of androgens.<9l Although testosterone is the major circulating androgen, and 
dihydrotestosterone (DHT) is the major nuclear androgen in the pilosebaceous unit and 
within hair follicles. DHT is formed in target cells from testosterone via Sa-reductase. 
3a-androstenediol is the peripheral metabolite of DHT, and its glucoronide, 3a-
androstenediol gluconide (3a-diolG) has been described as a marker of local androgen 
excess due to the increased activity of testosterone metabolism, simultaneously 
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increasing Sa-reductase activity in the cells of the hair follicle.0°l Although many 
studies have reported increased serum 3a.-diolG in women with cutaneous 
hyperandrogenism, its role as a marker of peripheral androgen action is still 
controversial. Furthermore, the manifestation of cutaneous hyperandrogenic stigmata 
can be influenced by the sensitivity of target tissues to androgens. As previously 
reported,0 2l there is evidence supporting that tissue response to androgen is determined 
by polymorphisms ofthe androgen receptor (AR)Y I) There also exist other explanations 
for the differences in the clinical presentation ofhyperandrogenism and biochemical 
values; significant variability among commercial immunoassays used for measuring 
serum androgen levels, along with a lack of standardization of androgen testing results 
may give rise to such discordances.06l It seems that the degree of cutaneous 
manifestations ofhyperandrogenism vary greatly among different ethnic populations. 
There have been suggestions in some reports, pointing to the notion that distinct ethnic 
groups may decidedly vary with respect to the concentrations of specific androgens in 
serum. Therefore, the intent of this review is to analyze the correlation between the 
severity of the cutaneous manifestations of hyperandrogenism, with focus on acne and 
hirsutism, with plasma levels of androgens .< ') 
1.2ACNE 
Acne vulgaris is a self-limiting disease affecting the sebaceous follicles. It is 
described in stages and associated with age in patients suffering from the condition. 
Acne has frequently been recognized as a disorder predominately seen in young adults, 
however, there has been a noted increase in related referrals of patients over 25 years of 
age.0 l Post adolescent acne is defined as the presence of acne after the age of 25, 
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regardless of age at onset. Late onset acne appears for the first time after the age of25 
years. (I) The pathogenic factors involved in this multifactorial disorder include; 
hyperkeratinization and obstruction of sebaceous follicles, resulting from abnormal 
keratinization of the infundibular epithelium, androgenic stimulation of sebaceous glands 
and microbial colonization of the pilosebaceous units with Propionbacterium acnes, 
which subsequently leads to perifollicular inflammation.(!) Acne does not appear without 
sebum, which serves as the nutrient source of P acnes, and androgens are the major 
sebotropic hormones.(l)(6)Increased sebum production in acne patients may be due to two 
main factors; (1) increased levels of circulating hormones and (2) hyper-responsiveness 
of the target organ, the pilosebaceous unit, to androgens, or both.(6)(1) 
Pathogenesis 
In the pathogenesis of acne, there are four key factors that have been recognized 
to contribute to the condition. The most important factor is increased sebum production 
as the sebaceous glands are tightly controlled by a complex endocrine system; especially 
influenced by androgens arising from the adrenals. This increased seborrhea may be due 
to an increase of circulating androgens. Secondly, obstruction of the pilosebaceous 
ducts, through which sebum passes to the surface of the skin. Bacterial colonization is 
the third factor giving rise to acne, in particular, colonization by Propionibacterium 
acnes. Lastly, the role played by such bacteria in the obstructive processY4) It is 
important to note that androgens enhance the production of sebum and follicular 
keratosis that in turn, plays the key role in acne etiology(S)(l2)(34) and anti-androgen 
therapy as a successful option in management of the disease.(S) 
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It is known that androgen hormones also contribute to the pathogenesis of acne. 
As such, the enzyme, Sa-reductase is present in the sebaceous glands and converts 
testosterone to the more potent receptor ligand, DHT. Many investigations have focused 
their attention on examining disturbed androgen production in the ovaries or adrenal 
glands, in addition to impaired plasma transport of androgens in women presenting with 
adult acne or acne associated with hirsutism.<') In patients with acne, it has been shown 
that the levels of androgen in serum are increased.O) Other possible mechanisms 
involved in the development of acne include increased sensitivity of the sebaceous end 
organs to androgen and an increased peripheral metabolism.(!) It is notable that in 
addition to the cosmetic concerns associated with acne, its presence may also imply 
underlying disorders. Reports have indicated a greater prevalence ofPCOS in patients 
with acne.CI)(2)(3) 
The frequency of acne in PCOS patients should be considered in correlation with 
hyperandrogenism, in a female acne patient with severe cutaneous manifestations, 
sudden onset and/or associated with hirsutism or irregular menstrual periods. Acne is 
recognized as a clinical manifestation of some endocrine diseasesY3) PCOS has the 
highest prevalence in acne. PCOS, according to the 2003 Rotterdam ESHRE/ASRM-
sponsored workshop established that two out of three of the following criteria should be 
met in order to fit the definition; chronic anovulation, clinical and/or biochemical 
hyperandrogenism, and polycystic ovaries on ultrasound examination.(!) 
With regards to the frequency of correlation between PCOS and acne 
manifestation, varying results have been seen in different studies. According to the 
study done by Ozdemir S, et al., concluded that the prevalence of acne in women with 
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PCOS was 53% with baseline results indicating that their study population of acneic 
women had higher median values ofDHEAS and FT than women without acne.<17) In 
comparison, in the results reported by Baldani DP, et al. , from their study, three groups 
were compared according to their acne severity, determined by the acne severity index 
(AS I). Women placed in Group A had an ASI of 1, indicating minor acne with a grade 
of < 1. Group B consisted of women with an ASI of2, indicating mild acne with a grade 
of 1-2.4 and Group C with an ASI of 3, indicating moderate acne with a total grade of 
2.5-4. Similarly to the above-mentioned study, mean serum FT levels were highest in 
Group C, while SHBG levels were lowest in Group c.< I) Notably, in the study done by 
Cibula D, et al, similarities in the obtained results were seen. Out of ninety women 
included in the study, a positive ultrasound finding of polycystic ovaries was found in 45 
(50%) of patients. LH/FSH ration> 1 was found in 34 (38%) of patients and most the 
most eminent finding was in 73 (81%) of patients had at least one androgen level 
elevated over the reference values. Furthermore, levels ofT, DHEA, DHEAS and 
androstenedione were elevated in 22 (24%), 17 (19%), 27 (30%) and 71 (79%) patients 
respectively. CS) Continuing with the results of this study, acne was graded as minor in 43 
(48%) cases, mild in 27 (30%) and moderate in 20 (22%). Additionally, 31 (34%) of 
women had an elevated index of free testosterone (IFT) .C5) The results obtained revealed 
that an increased LH/FSH ratio is a frequent laboratory sign in women with the 
polycystic ovary syndrome, consequently, the most common cause of 
hyperandrogenemia.<5) Thus, the important role of androgens in the etiology of acne 
was supported by the finding of 81% of women within the study were 
hyperandrogenic.<5) To conclude, although androgens play an important role in the 
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development of acne, an increased level of androgen production does not have an 
established effect on the degree of clinical manifestation of the disease. CS) Thus, it is 
important to note that these results in accordance to acne severity are inconclusive and 
do not offer a correlation between acne severity and hormone levels. 
1.3 HIRSUTISM 
Hirsutism is another common cutaneous expression of hyperandrogenism and is 
also, seen not only in PCOS, but also is one of the diagnosing characteristics. Hirsutism 
may be defined as "the medical term that refers to the presence of excessive (course) hair 
in androgen-dependent areas of the female body."C2) Hirsutism is one of the most 
common clinical conditions referred to endocrinologists, gynecologists and 
dermatologists by about 5-15% ofthe entire female population.C4) Structurally, there 
exist three types of hair. Covering the skin of the fetus is a soft hair known as lanugo 
hair and this disappears within the first months of postpartum life. Non-pigmented, soft, 
but larger than lanugo hairs, are vellus hairs and are generally <0.03mm in diameter. 
The third type of hairs are those known as terminal hairs, which are structurally longer, 
pigmented with a course texture. In humans they compose the hair of the eyebrows, 
eyelashes, scalp hair and pubic and axillary hair in both males and females, in addition to 
the body and facial hair in menYl 
Pathogenesis 
It is known that hair arises from the hair follicle, considered to be a highly 
productive organ with the ability to regenerate. The hair follicle has the capacity of 
regeneration, the hair cycle consisting of rhythmic repetitive growth, regression, and 
tissue remodeling.C2) Hair growth disorders seen in clinical practice represent the 
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undesirable alterations of this cycle. This includes, prolongation of the hair growth 
phase, known as anagen, and is noticed when vellus hairs evolve into terminal hairs, 
which gives notation to the term hirsutism. In contrast, shortening on the anagen phase 
is what leads to hair loss.C2) 
Androgens and hair growth 
The development and growth of sexual hair is largely dependent on the presence 
of androgens. Prior to puberty, vellus hair is small, straight and fair, without developed 
sebaceous glands. Due to the increased levels of androgens at the time of puberty, the 
vellus follicles in the pubic and axillary regions of the body ofboys and girls develop 
into terminal hairs, characteristically, larger, curlier and darker. Here, it is important to 
note that terminal hairs can be differentiated from vellus hairs, primarily by the length of 
the hair, in this case, longer than 0.5cm, and that terminal hairs are characteristically 
pigmented. (2) Androgens also increase the size of the sebaceous glands in areas such as 
the forehead and the cheeks, however the hair in these regions, remains vellus. This 
owes to the fact that differentiation patterns remain unexplained, androgens have 
paradoxically different effects on human hair follicles, depending on the area of the 
body.C2) As has already been mentioned, PCOS is the most common disorder associated 
with hyperandrogenism. In the analysis done by Escobar-Morreale H.F, et al., 70% of 
women presenting with the hirsute manifestations, also had PCOS.C2) It is of importance 
to mention that hirsutism is one of the diagnosing criteria in the guidelines for PCOS, as 
already reported according to the 2003 Rotterdam Criteria. In addition, 
hyperandrogenism or androgen excess corresponds with a common endocrinopathy, that 
affects between 5-10% ofwomen of reproductive age.0 3) Most commonly, women are 
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affected by PCOS as the most frequent hyperandrogenic disorder in 80-85% of women 
diagnosed with androgen excess.(l3) As reported, there exist three currently available 
definitions of the disorder, and hirsutism is included as a criterion in all of the available 
definitions. (!3) 
There exist several methods for the quantification and evaluation of hirsutism in 
women. Of several systems available for the scoring and/or grading of the degree of 
hirsutism, the modified Ferriman-Gallwey score (mFG) has now become the gold 
standard for evaluating and determining hirsutism.(2) The mFG method scores 9 of the 
11 body areas which include; the upper lip, chin, chest, upper and lower back, upper and 
lower abdomen, arm forearm, thigh and lower leg. Areas of the body without hair 
growth in the examined areas are given a score of 0. A score of 1 is given for minimally 
visible terminal hair growth, a score of2 if hair growth is more than minimal but not that 
ofthe equivalent to male growth in adults. A score of3 is given to presentation 
observed in a not very hairy male, while a score of 4 is given to patient with patterns 
typical of a well-virilized healthy adult males. Total scores range from 0 to 36. The 
grading of hirsutism has usually been agreed upon as; mild-having a score up to 15, 
moderate-from 16-25 and severe above 25.(2) Diagnosing hirsutism requires a cut-off 
value of the mFG score for establishing the diagnosis. Currently in practice today, 
clinicians choose a mFG more than or equal to 8, to indicate hirsutism.(2) It is important 
to note, however, that because terminal body hair can vary substantially from different 
races and ethnicities, the cut-off value should be adjusted to the population to which it is 
appliedY) 
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Figure 1 Schematic representation of the mFG score. 
Hirsutism is considered to be a direct marker of androgen excess, in particular, as 
the result of their action at the level of the pilosebecous unit. 
As reported in the study by Baldani D, et al. , the grouping for hirsute women followed 
that of acneic women. Mild hirsutism was defined as having a mFG score of 8-9 and 
these women were placed in Group A. Group B consisted of women with a moderate 
clinical presentation and an mFG score of 10-14. Group C encompassed women with 
severe hirsutism and an mFG score > 15. It was reported that the severity of hirsutism 
had a positive correlation with FT levels and negative correlation with SHBG, which 
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demonstrates that the severity of hirsutism is largely dependent on the bioavailability of 
unbound testosterone. Circulating androgen levels are not only reflected by the degree 
of hirsutism, but also by the intra-individual variation of such enzymes as Sa-reductase, 
which, in turn, affects the intracellular levels ofthe highly active androgen, DHT, in 
sebocytes and keratinocytes.0 ) In addition, according to Falsetti L, et al. , it has been 
documented from numerous studies that in hirsute women, Sa-reductase activity in the 
skin is constantly elevated. This enzyme, being responsible for the irreversible 
conversion ofT to DHT, is a key factor in hirsutism. Sa-reductase activity, and thus the 
formation ofDHT and Sa-reductase metabolites, for example, 3a-diolG is stimulated by 
high levels of circulating androgens.(2) This provides a crucial aspect in terms of 
determining and providing an adequate treatment. Comparatively, in the report by 
Meczekalski B, et al., the objective of the study being to assess the role of 3a-diolG as a 
marker of peripheral androgen action in young women with hirsutism as PCOS and as 
idiopathic hirsutism (IH) compared to controls, described significantly higher serum 
levels of 3a-diolG in comparison to the control. Similarly, FT was higher in PCOS 
women than in the controls. However, there was not a significant difference seen in 
serum 3a-diolG levels between PCOS and IH patients. In contrast, serum FT levels in 
PCOS patients were found to much higher than in IH patients.<2 ') As reported in the last 
mentioned study, it is of importance to understand the physiologic role of 3a-diolG. In 
order forT to be active in the skin, it must be converted to DHT by Sa-reductase. 3a-
diolG is one of the main metabolites ofDHT.<2 ' )(35) It has been reported, by Duffy, et al., 
that the skin is the major site of 3a-diolG and serum levels of 3a-diolG appear to mainly 
reflect skin DHT metabolism.<2 J)(36) Furthermore, Fassnacht, et al., reported amplified 
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Sa-reductase activity in PCOS, along with Carmina, et al., finding that 3a-dio!G showed 
a positive correlation with total testosterone and FT.<21X3?)(}S) 
In order to fully grasp the concept of the conditions of acne and hirsutism as 
clinical manifestations and the hormonal correlates involved, it is necessary to examine 
the different treatment options available thus far and the links they provide between the 
correlates. Hotmonal treatments for acne have proved to be popular in treatment of the 
disease by the process of lowering circulating and local androgen levels. Likewise, 
hormonal treatments are also able to oppose the effects of hormones on the sebaceous 
gland, as well, it is believed, on the follicular keratinocytes.<6) There are several options 
available in terms of providing hormonal therapy for the treatment of acne. Therapies 
include, anti-androgens, working on the level of blocking androgen receptors, agents 
which are formulated to decrease the endogenous production of androgens by the ovary 
or adrenal gland-for example, estrogens, combination oral contraceptives (OC), low-dose 
glucocorticoids, or gonadotropin-releasing hormone (GnRH) agonists.<6) In particular, 
the two main categories of drugs, anti-androgens and androgen inhibitors, will be 
discussed. 
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Table 1 Hormonal therapy and mechanism of action(6l 
I Hormonal Therapy I Mechanism of action 
Estrogens • Suppress ovarian production of 
androgens by suppressing pituitary 
gonadotropin release via negative 
feedback 
• Stimulates the hepatic synthesis of 
SHBG 
Cyproterone acetate (anti-androgen) • Ovulation inhibition 
• Androgen receptor blockade 
Flutamide (anti-androgen) • Androgen receptor blockade 
Spironolactone (anti-androgen) • Androgen receptor blockade 
• Sa-reductase inhibition 
Combined oral contraceptives • Ovarian androgen production 
inhibition 
• SHBG hepatic synthesis 
stimulation 
Oral glucocorticoids • Adrenal androgen production 
blockade 
GnRH agonists • Ovarian androgen production 
inhibition 
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Anti-androgens/androgen receptor blockers work on the level of directly and 
competitively inhibiting the binding ofT and DHT to its receptor. Such agents include 
cyproterone acetate, spironolactone and flutamide. Oral contraceptives inhibit 
circulating androgens by acting directly on ovarian function. Agents under the category 
of gonadotropin-releasing hormone agonists inhibit circulating androgens by acting on 
pituitary gland function. Oral glucocorticoids inhibit adrenal function , agents such as 
finasteride and ketoconazole inhibit peripheral androgen metabolism.<6X29) 
Cyproterone acetate (CPA) is a progestational anti-androgen working on the 
blockade of the androgen receptor. It is also the only anti-androgen that by acting on 
inhibiting ovulation, acts as an anti-gonadotrophin. The mechanism of action of CPA 
includes: (1) inhibiting the production of FSH and LH, which results in the blockage of 
ovarian function and thus reduces serum androgen levels, (2) inhibition ofDHT at its 
receptor, and (3) decreases the activity of.<6l<29) 
Spironolactone functions both as an androgen receptor blocker and inhibitor of 
Sa-reductase. Its anti-androgen affect is seen at the hair follicle where it competes for 
androgenic receptors and displaces DHT. It also has an effect on androgen metabolism 
resulting in the defective steroidogenesis and in turn, a decrease in ovarian testosterone 
production. It has been reported in some studies that up to 66% of women prescribed 
spironolactone, described improvement or complete clearing of acne.<29) Spironolactone, 
when used in combination with OCs, the results improved to up to 85%.<29) It has been 
reported to be effective in the treatment of mild to moderate hirsutism.<29) 
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Flutamide is considered to be a purely peripheral androgen antagonist. Some 
studies have reported significant decreases in T and DHEAS levels. This supports the 
hypothesis that flutamide may have a central role in reducing androgen synthesis and/or 
increasing androgen catabolism. Evidence suggests that flutamide changes hormonal 
levels exclusively in women with PCOS by decreasing T and DHEAS by 20% after 6 
months of treatment.C29) 
OCPs have long been used in the treatment of women with acne and are a 
common first line treatment. OCs generally contain an estrogen and progestin and work 
on the basis of suppressing ovulation, which in turn inhibits the production of androgens 
by the ovaries. OCs decrease serum androgen levels and therefore reduce sebum 
production. Increases in SHBG is also achieved by OCs with the consequent reduction 
of free testosterone.C6) Estrogen given in sufficient amounts will result in a decrease of 
sebum production, no matter what estrogen is used.C6) The treatment of acne and the 
results are found to be satisfactory, and hence, several OCs are approved for acne 
treatment.C29) In addition, it has been reported that within 6-9 months of use, 
inflammatory lesion counts were seen to be reduced by 30-60%, with improvement rates 
in 50-90% of patientsY9) In addition to its uses in the treatment of acne, reduction of 
serum androgens with OCs, also decreases new hair growth and in affect, slows down 
the growth of terminal hair that is already present.C29) Combination oral contraceptives 
(COCs) used in long term treatment has been effective in the treatment of acne and mild 
to moderate hirsutism with a mFG score less than or equal to 14. It has been reported in 
the literature by Falsetti L, et al., that patients with moderate and severe acne with PCOS 
treated with COCs for 18 to 24 cycles has shown to be effective.04) Furthermore, in 
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women with mild to moderate hirsutism, COCs have shown to reduce the mFG score by 
15 to 20% at 6 months, 50 to 60% at 24 months and 100% at 48 months.< 14) It is 
important to note that the efficacy of COCs is increased when combined with anti-
androgen treatment.<14) 
There are two modes of action of glucocorticoids in terms of acne treatment. For 
patients with inflammatory disease, shorter courses of a higher dose have been 
recommended and for those patients with adrenal hyperactivity, low dose corticosteroids 
have been used to suppress this process.<6) Therefore, oral corticosteroids can are 
considered to be inhibitors of adrenal function . Lastly, GnRH agonists, such as 
buserelin, nafarelin or leuproide, are agents that block androgen production by the ovary, 
hence, they block ovulation by interrupting the cyclic release ofFSH and LH from the 
pituitary.<6) However, due to the expense and side-effects of this treatment, GnRH 
agonists are reserved for their use in severe forms of androgenization. In addition, 
GnRH agonists in combination therapy with OCs has also resulted in the increase of 
SHBG and presents as a prolonged treatment option in hirsutism<29) as it was found to 
reduce the FetTiman-Gallwey score by 23% to 32.1% and hair diameter by 4.9-
63 .6%.04)(29) 
1.4 DISCUSSION 
It is evident that androgens are a crucial factor in the pathogenesis of acne and 
hirsutism. It has been proven that androgens have the capacity to potentiate increases in 
sebum production, which in turn results in follicular retention hyperkeratosis. In 
addition to this, we have seen that anti-androgen therapy is a highly successful treatment 
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of the disease. In patients with acne vulgaris, studies have shown that there exist 
elevations in TT, FT, DHEAS and A, which has also been attributed to other signs of 
hyperandrogenism, such as hirsutism, alopecia and and/or menstrual irregularities. 
However, it has been argued that although androgens have a key role in the etiology of 
acne, the role they play in terms of severity has not been well established. In some 
studies, a positive correlation has been shown between the levels of the adrenal 
androgen, DHEAs and a negative correlation with the levels of SHBG. In the study by 
Baldani DP, et al. , there was no association drawn between the grade of acne severity in 
correspondence to laboratory markers of androgen city .cl) According to the results taken 
from the aforementioned study, the degree of acne, as graded by the ASI score, showed a 
weak negative correlation with serum SHBG, correlating with the results of other, 
previous studies. It has also been recommended by other authors that SHBG levels be 
evaluated in women, in order to predict and select patients who may have a better 
response to appropriate hormone treatments. Also, all COCs decrease the level of LH 
while raising the level of SHBG. In addition, only contraceptives with anti-androgenic 
progestins; cyproterone acetate, chlormadinone acetate, or drosperinone, inhibit 
androgen receptors and affect Sa-reductase. However, it cannot be concluded that one 
androgen exclusively is connected with acne severity, at the same time, the correlation 
seen with SHBG is not considered significant. Furthermore, it can then be assumed that 
acne severity in patients with PCOS, can mostly be attributed to the peripheral 
sensitivity to androgens. Therefore, it is believed that patients with PCOS, treatment 
with anti androgenic contraceptives would be more beneficial. It should be kept in mind 
that acne pathogenesis is more complex than just the over-production of sebum and 
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abnormal duct keratinization. Changes in lipid composition, bacterial colonization with 
Propionbacterium acnes and the role of host immune response factors need to be 
considered. 
Hirsutism, defined as the manifestation of terminal hairs with a male pattern 
distribution seen in women, is reported to affect 5%-8% ofwomen of fertile age.< I)( I4) 
Because during puberty, androgens play a specific role in the transformation ofvellus 
into terminal hair, and the growth of terminal hair by prolonging the anagen phase in the 
androgen-dependent areas of the female body, hirsutism is thus considered a clinical 
marker of excess androgen levels. Various studies have reported the association 
between high levels of androgens and hirsutism, in comparison to low levels of SHBG.O) 
This correlation also corresponds to those results seen in the study by Baldani D, et al., 
which showed low levels of SHBG and elevated FT levels, as the most distinct signs of 
biochemical hyperandrogenism.<I) Similarly, there is also a poor correlation between the 
severity of hirsutism and the level of androgen excess, as reported by the majority of 
investigations.0)<26)(27) The study by Baldani D, et al., showed that, although there was 
not a significant relationship between mFG score and LH, FSH, TT, androstenedione 
and DHEA, the severity of hirsutism showed a possible correlation with FT and a 
negative correlation with SHBG which gives rise to the notion that hirsutism severity 
can mainly be attributed to the bioavailability ofunbound testosterone.O) As the degree 
of hirsutism indicates the level of circulating androgens, it is also seen to be affected by 
intraindividual variation of Sa-reductase levels, in turn affecting the intracellular levels 
ofDHT in sebocytes and keratinocytes .<I) It was found, in the study of interest, that 
there was no correlation between the levels of excess 3a.-diolG and hirsutism severity _<I) 
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3a-diolG seems to largely reflect adrenal androgen secretion, however, it is not found to 
reflect primary peripheral Sa-reductase activity.(!) Thus, 3a-diolG measurements may be 
useful solely in monitoring therapy using Sa-reductase inhibitors. When choosing 
treatment options for patients with over-all androgenic symptoms, treatments of choice 
include those that elevate levels of SHBG.0 ) 
I .S CONCLUSION 
Even though excess androgen levels play a significant role in the manifestation of 
acne, in PCOS patients, the degree of severity cannot be linearly associated with serum 
androgen levels. Their levels, should not, therefore be used in determining the dosage of 
anti-androgen therapy. In the PCOS patient, the significant negative correlation 
observed between serum SHBG levels and the degree of hirsutism, gives rise to the fact 
that hormonal contraception, which increases SHBG levels, should be the therapy of 
choice in treating the PCOS patient. 
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